Your browser doesn't support javascript.
loading
APC-ß-catenin-TCF signaling silences the intestinal guanylin-GUCY2C tumor suppressor axis.
Blomain, Erik S; Rappaport, Jeffrey A; Pattison, Amanda M; Bashir, Babar; Caparosa, Ellen; Stem, Jonathan; Snook, Adam E; Waldman, Scott A.
Affiliation
  • Blomain ES; Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA, USA.
  • Rappaport JA; Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA, USA.
  • Pattison AM; Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA, USA.
  • Bashir B; Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA, USA.
  • Caparosa E; Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA, USA.
  • Stem J; Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA, USA.
  • Snook AE; Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA, USA.
  • Waldman SA; Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA, USA.
Cancer Biol Ther ; 21(5): 441-451, 2020 05 03.
Article in En | MEDLINE | ID: mdl-32037952
ABSTRACT
Sporadic colorectal cancer initiates with mutations in APC or its degradation target ß-catenin, producing TCF-dependent nuclear transcription driving tumorigenesis. The intestinal epithelial receptor, GUCY2C, with its canonical paracrine hormone guanylin, regulates homeostatic signaling along the crypt-surface axis opposing tumorigenesis. Here, we reveal that expression of the guanylin hormone, but not the GUCY2C receptor, is lost at the earliest stages of transformation in APC-dependent tumors in humans and mice. Hormone loss, which silences GUCY2C signaling, reflects transcriptional repression mediated by mutant APC-ß-catenin-TCF programs in the nucleus. These studies support a pathophysiological model of intestinal tumorigenesis in which mutant APC-ß-catenin-TCF transcriptional regulation eliminates guanylin expression at tumor initiation, silencing GUCY2C signaling which, in turn, dysregulates intestinal homeostatic mechanisms contributing to tumor progression. They expand the mechanistic paradigm for colorectal cancer from a disease of irreversible mutations in APC and ß-catenin to one of guanylin hormone loss whose replacement, and reconstitution of GUCY2C signaling, could prevent tumorigenesis.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Colorectal Neoplasms / Adenomatous Polyposis Coli Protein / Natriuretic Peptides / Beta Catenin / TCF Transcription Factors / Receptors, Enterotoxin / Gastrointestinal Hormones / Intestinal Mucosa Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Cancer Biol Ther Journal subject: NEOPLASIAS / TERAPEUTICA Year: 2020 Document type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Colorectal Neoplasms / Adenomatous Polyposis Coli Protein / Natriuretic Peptides / Beta Catenin / TCF Transcription Factors / Receptors, Enterotoxin / Gastrointestinal Hormones / Intestinal Mucosa Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Cancer Biol Ther Journal subject: NEOPLASIAS / TERAPEUTICA Year: 2020 Document type: Article Affiliation country: United States